Hemorrhagic Shock - Pipeline Review, H2 2016

  • ID: 3846536
  • Drug Pipelines
  • 38 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Leading BioSciences, Inc.
  • NuvOx Pharma LLC
  • MORE
Hemorrhagic Shock - Pipeline Review, H2 2016

Summary

‘Hemorrhagic Shock - Pipeline Review, H2 2016’, provides an overview of the Hemorrhagic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Shock
- The report reviews pipeline therapeutics for Hemorrhagic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hemorrhagic Shock therapeutics and enlists all their major and minor projects
- The report assesses Hemorrhagic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hemorrhagic Shock

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Leading BioSciences, Inc.
  • NuvOx Pharma LLC
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hemorrhagic Shock Overview

Therapeutics Development

Pipeline Products for Hemorrhagic Shock - Overview

Pipeline Products for Hemorrhagic Shock - Comparative Analysis

Hemorrhagic Shock - Therapeutics under Development by Companies

Hemorrhagic Shock - Therapeutics under Investigation by Universities/Institutes

Hemorrhagic Shock - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Hemorrhagic Shock - Products under Development by Companies

Hemorrhagic Shock - Products under Investigation by Universities/Institutes

Hemorrhagic Shock - Companies Involved in Therapeutics Development

Biomedica Management Corporation

Leading BioSciences, Inc.

NuvOx Pharma LLC

Hemorrhagic Shock - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AM/AMBP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-1148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutrolide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVX-408 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YW-356 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemorrhagic Shock - Dormant Projects

Hemorrhagic Shock - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Hemorrhagic Shock, H2 2016

Number of Products under Development for Hemorrhagic Shock - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Hemorrhagic Shock - Pipeline by Biomedica Management Corporation, H2 2016

Hemorrhagic Shock - Pipeline by Leading BioSciences, Inc., H2 2016

Hemorrhagic Shock - Pipeline by NuvOx Pharma LLC, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hemorrhagic Shock - Dormant Projects, H2 2016

Hemorrhagic Shock - Discontinued Products, H2 2016 36List of Figures

Number of Products under Development for Hemorrhagic Shock, H2 2016

Number of Products under Development for Hemorrhagic Shock - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Leading BioSciences, Inc.
  • NuvOx Pharma LLC
  • MORE
Hemorrhagic Shock Hypovolemic shock, also called hemorrhagic shock, is a life-threatening condition that results when loses more than 20 percent of body’s blood or fluid supply. Symptoms include anxiety, dizziness, confusion, chest pain, loss of consciousness, low blood pressure, rapid heart rate and weak pulse.

Hemorrhagic Shock pipeline therapeutics constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Our latest report Hemorrhagic Shock – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Biomedica Management Corporation
Leading BioSciences, Inc.
NuvOx Pharma LLC
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll